Literature DB >> 24238837

Bilateral implant reconstruction does not affect the quality of postmastectomy radiation therapy.

Alice Y Ho1, Nisha Patel2, Nisha Ohri3, Monica Morrow4, Babak J Mehrara5, Joseph J Disa5, Peter G Cordeiro5, Weiji Shi6, Zhigang Zhang6, Daphna Gelblum7, Claire T Nerbun8, Katherine M Woch8, Ase Ballangrud8, Beryl McCormick7, Simon N Powell7.   

Abstract

To determine if the presence of bilateral implants, in addition to other anatomic and treatment-related variables, affects coverage of the target volume and dose to the heart and lung in patients receiving postmastectomy radiation therapy (PMRT). A total of 197 consecutive women with breast cancer underwent mastectomy and immediate tissue expander (TE) placement, with or without exchange for a permanent implant (PI) before radiation therapy at our center. PMRT was delivered with 2 tangential beams + supraclavicular lymph node field (50Gy). Patients were grouped by implant number: 51% unilateral (100) and 49% bilateral (97). The planning target volume (PTV) (defined as implant + chest wall + nodes), heart, and ipsilateral lung were contoured and the following parameters were abstracted from dose-volume histogram (DVH) data: PTV D95% > 98%, Lung V20Gy > 30%, and Heart V25Gy > 5%. Univariate (UVA) and multivariate analyses (MVA) were performed to determine the association of variables with these parameters. The 2 groups were well balanced for implant type and volume, internal mammary node (IMN) treatment, and laterality. In the entire cohort, 90% had PTV D95% > 98%, indicating excellent coverage of the chest wall. Of the patients, 27% had high lung doses (V20Gy > 30%) and 16% had high heart doses (V25Gy > 5%). No significant factors were associated with suboptimal PTV coverage. On MVA, IMN treatment was found to be highly associated with high lung and heart doses (both p < 0.0001), but implant number was not (p = 0.54). In patients with bilateral implants, IMN treatment was the only predictor of dose to the contralateral implant (p = 0.001). In conclusion, bilateral implants do not compromise coverage of the target volume or increase lung and heart dose in patients receiving PMRT. The most important predictor of high lung and heart doses in patients with implant-based reconstruction, whether unilateral or bilateral, is treatment of the IMNs. Refinement of radiation techniques in reconstructed patients who require comprehensive nodal irradiation is warranted.
Copyright © 2014 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Breast cancer; Immediate reconstruction; Implant; Postmastectomy radiation

Mesh:

Year:  2013        PMID: 24238837     DOI: 10.1016/j.meddos.2013.08.008

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  4 in total

1.  Should Immediate Autologous Breast Reconstruction Be Considered in Women Who Require Postmastectomy Radiation Therapy? A Prospective Analysis of Outcomes.

Authors:  Jessica Billig; Reshma Jagsi; Ji Qi; Jennifer B Hamill; Hyungjin M Kim; Andrea L Pusic; Edward Buchel; Edwin G Wilkins; Adeyiza O Momoh
Journal:  Plast Reconstr Surg       Date:  2017-06       Impact factor: 4.730

Review 2.  Radiation-Induced Tissue Damage: Clinical Consequences and Current Treatment Options.

Authors:  Hillary Nepon; Tyler Safran; Edward M Reece; Amanda M Murphy; Joshua Vorstenbosch; Peter G Davison
Journal:  Semin Plast Surg       Date:  2021-09-10       Impact factor: 2.195

3.  Survival comparison between postoperative and preoperative radiotherapy for stage I-III non-inflammatory breast cancer.

Authors:  Yuxi Zhang; Zhipeng Xu; Hui Chen; Xinchen Sun; Zhaoyue Zhang
Journal:  Sci Rep       Date:  2022-08-22       Impact factor: 4.996

4.  Reduction in low-dose to normal tissue with the addition of deep inspiration breath hold (DIBH) to volumetric modulated arc therapy (VMAT) in breast cancer patients with implant reconstruction receiving regional nodal irradiation.

Authors:  Vishruta A Dumane; Kitwadee Saksornchai; Ying Zhou; Linda Hong; Simon Powell; Alice Y Ho
Journal:  Radiat Oncol       Date:  2018-09-24       Impact factor: 3.481

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.